- Market Realist•14 hours ago
The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.
- Market Realist•yesterday
Novartis's (NVS) revenues fell 1% on a constant currency basis for 3Q16 as compared to 3Q15.
Investopedia looks at the top drug patents about to expire in 2017
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||71.21 - 72.05|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||25.38|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|